Gilead Agrees to Pay $97 Million to Resolve Alleged False Claims Act Liability for Paying Kickbacks
California-based pharmaceutical company Gilead Sciences has agreed to pay $97 million to resolve claims that it violated the False Claims Act by illegally using a charitable foundation as a conduit to pay the copays of thousands of Medicare patients taking Gilead’s pulmonary arterial hypertension drug, Letairis.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every Brief, six days a week.